Fig. 2.

In vivo efficacy of DAPPD in APP/PS1 mice. (A and B) Survival and body weight of vehicle- or DAPPD-treated WT and APP/PS1 mice during the treatment period. (C and D) Escape-latency time and distance traveled of each group in the MWM test. (E) Representative swimming paths on the 10th day of training. (F and G) Time spent in target platform and quadrants and representative swimming paths from the probe trials. (H–J) Number of times each animal entered the target zone (H), distance traveled (I), and swim speed (J) during the 60-s probe trial. (K) Analysis of the amounts of Aβ plaques, detected by ThS or 6E10, after the daily treatments of DAPPD for 2 mo (2 mg/kg/day; i.p.) in APP/PS1 mice starting at 7.5 mo of age. (Scale bars, 200 μm.) Animal number: A, D, F, and H–J: n = 10 per group; K, n = 4 per group. *P < 0.05; **P < 0.01; ***P < 0.001 by Student’s t test or repeated-measures ANOVA, Tukey’s post hoc test. All error bars indicate SEM.